Although TMB was higher in NFE2L2 mutated patients than in wild-type patients in three pan-cancer cohorts, there was no statistically significant association between NFE2L2 MU and worse survival in the MSK1661 cohort. This evidence concerns the gene NFE2L2 and cancer.